Research Article: Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system
Abstract:
Background: Linear IgA bullous dermatosis (LABD) is a rare autoimmune blistering disease. The induction of LABD by medications is a critical issue, with previous studies highlighting the link between specific drugs and the onset of LABD. This study aims to assess the reported associations between LABD and numerous available medications using the FDA adverse event reporting system (FAERS).
No summary available.